Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an oral tablet for systemic use. It is indicated for the prophylaxis of cerebral vasospasm in patients who have suffered a subarachnoid hemorrhage, helping to preserve cerebral blood flow.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards to provide reliable sourcing across multiple regions for global healthcare providers and ensure compliance with regulatory requirements.

Nimotop (nimodipine) is used in the management of cerebrovascular conditions, specifically to prevent vasospasm after bleeding in the brain. - Cerebral vasospasm after subarachnoid hemorrhage: reduces narrowing of cerebral arteries and helps maintain adequate cerebral perfusion. - Delayed cerebral ischemia following aneurysmal SAH: lowers the incidence of secondary ischemic neurological deficits. - Neuroprotective support in acute brain injury: may improve cerebral blood flow and oxygen delivery during the early recovery phase.

Nimotop may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often reported during therapy. - Hypotension: transient lowering of blood pressure, especially when standing. - Nausea: occasional stomach upset or queasiness. - Flushing: warm sensation and reddening of the skin. - Dizziness: feeling light‑headed or unsteady. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: abnormally slow heart rate that may need intervention. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Liver enzyme elevation: increased transaminases indicating hepatic stress. - Myocardial infarction: rare occurrence of heart attack. - Thrombocytopenia: low platelet count leading to bleeding risk.

Before prescribing Nimotop, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; assess liver enzymes regularly. - Concomitant antihypertensives: risk of additive blood‑pressure lowering effects. - Elderly patients: increased sensitivity to hypotension; start at lower dose if applicable. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Nimotop can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase plasma concentrations. - Other calcium channel blockers: additive vasodilatory and hypotensive effects. - Grapefruit juice: can raise drug levels and risk of adverse events.

Moderate Interactions (Monitor Closely): - Beta‑blockers: monitor heart rate and blood pressure for excessive slowing. - Diuretics: watch for enhanced hypotensive response. - Antihypertensive agents: dose adjustments may be required to avoid over‑lowering blood pressure.